Onxeo S.A. announced the appointment of Dr. Shefali Agarwal as Chief Executive Officer. Dr. Agarwal succeeds Julien Miara, a Principal at Invus SAS, who was named interim CEO in January 2022. Dr. Agarwal is a physician by training, and, until recently, was the Chief Medical and Development Officer at Epizyme Inc., a biopharmaceutical company developing novel epigenetic therapies for cancer, where she led global clinical development and regulatory strategy.

She will remain an advisor to Epizyme in a consultant role while fulfilling her duties at Onxeo. She is also on the Scientific Advisory Board of Imvax Inc. and is the Founder of Cancer Shakti Foundation, a voluntary non-profit organization dedicated to raising cancer awareness.